Abbvie Inc
NYSE: ABBV
$193.47
-$0.15 (-0.1%)
Closing Price on September 20, 2024
ABBV Articles
The short interest data have been released for the July 31 settlement date, and for most of the selected pharmaceutical stocks, short interest decreased.
Published:
Independent research firm Argus has maintained its Buy rating and its $85.00 price target on AbbVie.
Published:
ThinkstockThe short interest data have been released for the July 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market...
Published:
Last Updated:
AbbVie reported better-than-expected second-quarter financial results Friday before the markets opened.
Published:
Abbvie is scheduled to report its second-quarter financial results before the markets open Friday.
Published:
Earnings season is hitting its stride next week, and the health care sector, the biotech stocks in particular, have been on a roll for the past 12 months.
Published:
Last Updated:
A new report from Jefferies updates the firm's top global pharmaceutical stocks to buy, and these picks make sense for investors now.
Published:
The June 30 short interest data have been compared with the previous figures, and across the selected pharmaceutical stocks, short interest decreased.
Published:
A new report from UBS highlights three stocks that the firm likes best now. Not only do they all pay a solid dividend and have a good potential for growth, they all could help cushion a portfolio...
Published:
How much are big pharmaceutical companies really spending to get their drugs out there in the public eye?
Published:
The June 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
Published:
We screened the Jefferies Franchise Pick List for top stocks rated Buy with the highest upside to the Jefferies price targets.
Published:
The May 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest is down.
Published:
AT&T continued to reign as the most shorted stock trading on the New York Stock Exchange between the May 15 and May 29 settlement dates.
Published:
Credit Suisse has updated its autoimmune market model and it sees implications for all of the large cap U.S. pharmaceutical companies in its coverage.
Published: